| Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis MA Boyd, CL Moore, JM Molina, R Wood, JS Madero, M Wolff, ... The lancet HIV 2 (2), e42-e51, 2015 | 89 | 2015 |
| Randomized trial of BCG vaccine to protect against Covid-19 in health care workers LF Pittet, NL Messina, F Orsini, CL Moore, V Abruzzo, S Barry, R Bonnici, ... New England Journal of Medicine 388 (17), 1582-1596, 2023 | 71 | 2023 |
| Rates of combination antiretroviral treatment change in Australia, 1997–2000 Australian HIV Observational Database HIV medicine 3 (1), 28-36, 2002 | 59 | 2002 |
| Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy A Martin, C Moore, PWG Mallon, J Hoy, S Emery, W Belloso, ... Aids 27 (15), 2403-2411, 2013 | 49 | 2013 |
| A new method for assessing how sensitivity and specificity of linkage studies affects estimation CL Moore, J Amin, HF Gidding, MG Law PloS one 9 (7), e103690, 2014 | 45 | 2014 |
| Early antiretroviral therapy with raltegravir generates sustained reductions in HIV reservoirs but not lower T-cell activation levels WJ Hey-Cunningham, JM Murray, V Natarajan, J Amin, CL Moore, ... Aids 29 (8), 911-919, 2015 | 42 | 2015 |
| Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial PDJ Bollen, CL Moore, HA Mujuru, S Makumbi, AR Kekitiinwa, E Kaudha, ... The Lancet HIV 7 (8), e533-e544, 2020 | 40 | 2020 |
| Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 … J Amin, MA Boyd, N Kumarasamy, CL Moore, MH Losso, CA Nwizu, ... PLoS One 10 (2), e0118228, 2015 | 36 | 2015 |
| Mental health and wellbeing coordinators in primary schools to support student mental health: protocol for a quasi-experimental cluster study S Darling, G Dawson, J Quach, R Smith, A Perkins, A Connolly, A Smith, ... BMC Public Health 21, 1-14, 2021 | 33 | 2021 |
| ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested … CL Moore, A Turkova, H Mujuru, A Kekitiinwa, A Lugemwa, CM Kityo, ... BMC infectious diseases 21, 1-14, 2021 | 32 | 2021 |
| Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority … H Waalewijn, MK Chan, PDJ Bollen, HA Mujuru, S Makumbi, ... The Lancet HIV 9 (5), e341-e352, 2022 | 28 | 2022 |
| Off‐target effects of bacillus Calmette–Guérin vaccination on immune responses to SARS‐CoV‐2: implications for protection against severe COVID‐19 NL Messina, S Germano, R McElroy, R Rudraraju, R Bonnici, LF Pittet, ... Clinical & translational immunology 11 (4), e1387, 2022 | 26 | 2022 |
| Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents and young adults (BREATHER): Extended follow-up results of a randomised, open-label … A Turkova, CL Moore, K Butler, A Compagnucci, Y Saïdi, V Musiime, ... PLoS One 13 (4), e0196239, 2018 | 23 | 2018 |
| Hospitalization for anxiety and mood disorders in HIV-infected and-uninfected gay and bisexual men CL Moore, AE Grulich, G Prestage, HF Gidding, F Jin, K Petoumenos, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 73 (5), 589-597, 2016 | 21 | 2016 |
| Antiretroviral resistance after first-line antiretroviral therapy failure in diverse HIV-1 subtypes in the SECOND-LINE Study EP Lam, CL Moore, E Gotuzzo, C Nwizu, A Kamarulzaman, ... AIDS research and human retroviruses 32 (9), 841-850, 2016 | 21 | 2016 |
| Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial P Amuge, A Lugemwa, B Wynne, HA Mujuru, A Violari, CM Kityo, ... The Lancet HIV 9 (9), e638-e648, 2022 | 20 | 2022 |
| Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority … A Turkova, H Waalewijn, MK Chan, PDJ Bollen, ... The Lancet HIV 9 (9), e627-e637, 2022 | 19 | 2022 |
| Bone mineral density over 96 weeks in adults failing first-line therapy randomized to raltegravir/lopinavir/ritonavir compared with standard second-line therapy H Haskelberg, PWG Mallon, J Hoy, J Amin, C Moore, P Phanuphak, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 67 (2), 161-168, 2014 | 18 | 2014 |
| Poor record linkage sensitivity biased outcomes in a linked cohort analysis CL Moore, HF Gidding, MG Law, J Amin Journal of clinical epidemiology 75, 70-77, 2016 | 15 | 2016 |
| HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r)+ 2–3 nucleoside/nucleotide reverse transcriptase inhibitors (N (t) RTI) or LPV/r+ raltegravir as … A Martin, CL Moore, PWG Mallon, JF Hoy, S Emery, WH Belloso, ... PLoS One 8 (10), e77138, 2013 | 15 | 2013 |
